Smyth R, Walters S
Institute of Child health, University of Liverpool, Alder Hey Children's Hospital, Eaton Road, Liverpool, Merseyside, UK, L12 2AP.
Cochrane Database Syst Rev. 2000(2):CD000406. doi: 10.1002/14651858.CD000406.
Poor nutrition occurs frequently in children and adults with cystic fibrosis and is associated with a number of other adverse outcomes. Oral calorie supplements are used to try and increase total daily calorie intake and improve weight gain. However, they are expensive and there are concerns that they may lead to a reduction in the amount of food eaten and no overall improvement in energy intake.
To examine the evidence that in patients with cystic fibrosis, oral calorie supplements increase daily calorie intake, improve overall nutritional intake, nutritional indices, lung function, survival and quality of life. To assess possible adverse effects associated with use of oral calorie supplements.
The Cochrane Cystic Fibrosis and Genetic Disorders Group specialist trials register which comprises references identified from comprehensive electronic database searches, handsearching relevant journals and handsearching abstract books of conference proceedings. The companies which market oral calorie supplements were also contacted. Date of the most recent search of the Group's specialised register: November 1999.
All randomised or quasi-randomised controlled trials comparing use of oral calorie supplements for at least one month to increase calorie intake with no specific intervention or additional nutritional advice in patients with cystic fibrosis.
The following outcomes were assessed: indices of nutrition and growth, anthropometric measures of body composition, calorie intake (total, from oral calorie supplements and from food), nutrient intake, eating behaviour, quality of life, specific adverse effects, lung function and mortality.
Two trials which reported results from a total of 29 patients were suitable for inclusion in the review. From the data provided in the published reports only one item (change in weight) could be extracted from one trial for inclusion in the review. This showed no difference between intervention and comparison group.
REVIEWER'S CONCLUSIONS: Oral calorie supplements are very widely used around the world in an attempt to improve nutritional status in patients with cystic fibrosis, at some considerable cost. It is therefore very disappointing that their effectiveness has not been assessed by adequate clinical trials. No conclusions can be made about the use of oral calorie supplements in cystic fibrosis from the information currently available and clinicians must balance potential benefits against possible adverse effects of treatment in making decisions about individual patients. This systematic review has clearly identified the need for a well designed, adequately-powered, multicentre, randomised controlled trial assessing the effectiveness and possible adverse effects of oral calorie supplements in cystic fibrosis.
营养不良在患有囊性纤维化的儿童和成人中经常出现,并与许多其他不良后果相关。口服热量补充剂被用于尝试增加每日总热量摄入并改善体重增加。然而,它们价格昂贵,并且有人担心它们可能导致食物摄入量减少,且能量摄入没有整体改善。
研究证据表明,对于囊性纤维化患者,口服热量补充剂可增加每日热量摄入、改善整体营养摄入、营养指标、肺功能、生存率和生活质量。评估与使用口服热量补充剂相关的可能不良反应。
Cochrane囊性纤维化和遗传疾病小组专业试验注册库,其中包括从全面的电子数据库搜索、手工检索相关期刊以及手工检索会议论文摘要书中识别出的参考文献。还联系了销售口服热量补充剂的公司。该小组专业注册库最近一次检索日期:1999年11月。
所有比较使用口服热量补充剂至少一个月以增加热量摄入与囊性纤维化患者无特定干预或额外营养建议的随机或半随机对照试验。
评估了以下结果:营养和生长指标、身体成分的人体测量指标、热量摄入(总量、来自口服热量补充剂和食物)、营养摄入、饮食行为、生活质量、特定不良反应、肺功能和死亡率。
两项试验共报告了29名患者的结果,适合纳入本综述。从已发表报告中提供的数据来看,只能从一项试验中提取一项(体重变化)纳入综述。这表明干预组和对照组之间没有差异。
口服热量补充剂在世界各地被广泛使用,试图改善囊性纤维化患者的营养状况,但成本相当高。因此,它们的有效性尚未通过充分的临床试验进行评估,这非常令人失望。根据目前可得的信息,无法就口服热量补充剂在囊性纤维化中的使用得出结论,临床医生在为个体患者做决策时必须权衡治疗的潜在益处与可能的不良反应。这项系统综述明确指出需要进行一项设计良好、样本量充足的多中心随机对照试验,以评估口服热量补充剂在囊性纤维化中的有效性和可能的不良反应。